Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Commercial Officer | March 01, 2019 | March 05, 2019 |
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Director | June 24, 2026 | June 27, 2026 |
| MBX Biosciences, Inc.MBX · Entity 4247 | Director · President and CEO | August 03, 2026 | August 04, 2026 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | Director | January 02, 2026 | January 06, 2026 |
| Yarrow Bioscience, Inc.YARW · Entity 6871 | Director | July 27, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date March 01, 2019 · Filed March 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 10,941 |
Ending reported balance
After 2019-03-04 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-03-01 · Exercise / conversion · Acquired 5,000 · Balance 15,941 Row 2 · 2019-03-01 · Sale · Disposed 5,000 · Balance 10,941 Row 3 · 2019-03-04 · Exercise / conversion · Acquired 5,000 · Balance 15,941 Row 4 · 2019-03-04 · Sale · Disposed 5,000 · Balance 10,941 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.76 · Expires 2026-02-15 | Direct | 55,650 |
Reported balance
After 2019-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-03-01 · Exercise / conversion · Disposed 5,000 · Balance 55,650 F1: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.76 · Expires 2026-02-15 | Direct | 50,650 |
Reported balance
After 2019-03-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-03-04 · Exercise / conversion · Disposed 5,000 · Balance 50,650 F1: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.
C4 Therapeutics, Inc.
Report date June 24, 2026 · Filed June 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2036-06-23 | Direct | 62,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 62,000 · Balance 62,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.
MBX Biosciences, Inc.
Report date August 03, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,938 |
Reported balance
After 2026-08-03 transaction · row 1
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 71,000 · Balance 82,938 F1: Represents the grant of restricted stock units ("RSUs"). 25% of the shares subject to the RSU grant will vest annually over four years, on each July 13, 2027, 2028, 2029 and 2030, subject to continued service on each such vesting date. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.41 · Expires 2036-08-03 | Direct | 331,000 |
Reported balance
After 2026-08-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-03 · Grant · Acquired 331,000 · Balance 331,000 F3: The options will vest and become exercisable with 25% of the shares subject to the award vesting on July 13, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectTrust | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,000 F2: Shares held by the Steven L Hoerter Revocable Trust dated November 2, 2018, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"). 25% of the shares subject to the RSU grant will vest annually over four years, on each July 13, 2027, 2028, 2029 and 2030, subject to continued service on each such vesting date.
F2: Shares held by the Steven L Hoerter Revocable Trust dated November 2, 2018, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F3: The options will vest and become exercisable with 25% of the shares subject to the award vesting on July 13, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each such vesting date.
Oric Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2036-01-01 | Direct | 40,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 40,000 · Balance 40,000 F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.
Yarrow Bioscience, Inc.
Report date July 27, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.19 · Expires 2036-04-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-27 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer"). F2: Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time. F3: This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
F2: Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.
F3: This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 23, 2021 · Amendment
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.05 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 26,342 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Deciphera Pharmaceuticals, Inc.
Report date June 11, 2024 · Filed June 12, 2024
Section 16 reporting ended · disclosed 2024-06-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-06-11 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-06-11 · Grant · Acquired 286,075 · Balance 358,838 F1: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred. Row 2 · 2024-06-11 · Disposition to issuer · Disposed 286,075 · Balance 72,763 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Row 3 · 2024-06-11 · Other · Disposed 72,763 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.40 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-11 · Disposition to issuer · Disposed 395,735 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.23 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-11 · Disposition to issuer · Disposed 270,357 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-06-11 · Disposition to issuer · Disposed 415,000 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.48 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-06-11 · Disposition to issuer · Disposed 250,000 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.92 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-06-11 · Disposition to issuer · Disposed 298,100 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred.
F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding.
F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Ignyta, Inc.
Report date February 08, 2018 · Filed February 12, 2018
Section 16 reporting ended · disclosed 2018-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2026-12-07 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-08 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2027-06-12 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-08 · Disposition to issuer · Disposed 11,666 · Balance 0 F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2018 Filed May 21, 2018 20:24 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $25.73 | $0.00 |
DisclosureSEC source: 0000899243-18-013552 · doc4.xml · derivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 36 equal monthly installments following the vesting commencement date of May 17, 2018, subject to continued service through such dates. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 2,050 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001209191-18-026071 · doc4.xml · derivative · entry 3 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,850 Underlying: Common stock · 2,050 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,050 | $85.95 | $176,197.50 |
DisclosureSEC source: 0001209191-18-026071 · doc4.xml · nonDerivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 20:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,050 | $39.76 | $81,508.00 |
DisclosureSEC source: 0001209191-18-026071 · doc4.xml · nonDerivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 20:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 2,050 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001209191-18-021611 · doc4.xml · derivative · entry 3 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,900 Underlying: Common stock · 2,050 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 20:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,050 | $84.65 | $173,532.50 |
DisclosureSEC source: 0001209191-18-021611 · doc4.xml · nonDerivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 20:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,050 | $39.76 | $81,508.00 |
DisclosureSEC source: 0001209191-18-021611 · doc4.xml · nonDerivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:45 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 2,050 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001209191-18-013400 · doc4.xml · derivative · entry 3 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,950 Underlying: Common stock · 2,050 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:45 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,050 | $78.63 | $161,191.50 |
DisclosureSEC source: 0001209191-18-013400 · doc4.xml · nonDerivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:45 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,050 | $39.76 | $81,508.00 |
DisclosureSEC source: 0001209191-18-013400 · doc4.xml · nonDerivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011249 · doc4.xml · derivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common stock · 8,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 33,000 | $0.00 Strike: $77.70 | $0.00 |
DisclosureSEC source: 0001209191-18-011249 · doc4.xml · derivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common stock · 33,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:31 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,666 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001209191-18-009144 · doc4.xml · derivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,666 shares Expires 2027-06-12 F1 · derivative.exercise_date: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:31 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001209191-18-009144 · doc4.xml · derivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:16 UTC Amendment | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001209191-18-005432 · doc4a.xml · derivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common stock · 25,000 shares Expires 2016-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The original Form 4, filed on January 25, 2018, stated that 25,000 derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of 25,000 derivative securities. This Form 4 amendment is to solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001209191-18-005360 · doc4.xml · derivative · entry 3 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common stock · 25,000 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 25,000 | $74.83 | $1,870,750.00 |
DisclosureSEC source: 0001209191-18-005360 · doc4.xml · nonDerivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 25,000 | $39.76 | $994,000.00 |
DisclosureSEC source: 0001209191-18-005360 · doc4.xml · nonDerivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 13, 2017 Filed Jun 20, 2017 00:16 UTC | Ignyta, Inc. RXDX · Entity 169521 | GrantStock Option (Right to Buy) · Derivative | 11,666 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001209191-17-040968 · doc4.xml · derivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,666 Underlying: Common Stock · 11,666 shares Expires 2027-06-12 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (6/13/2018), or the next annual meeting of the stockholders, if earlier, subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 47,600 | $0.00 Strike: $50.40 | $0.00 |
DisclosureSEC source: 0001209191-17-013749 · doc4.xml · derivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,600 Underlying: Common stock · 47,600 shares Expires 2027-02-20 F1 · derivative.exercise_date: This option was granted on February 21, 2017. The shares underlying this option vest as to 25% of the underlying shares on February 21, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 08, 2016 Filed Dec 10, 2016 00:51 UTC | Ignyta, Inc. RXDX · Entity 169521 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001209191-16-154551 · doc4.xml · derivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: The option is exercisable as it vests. 33 1/3% of the shares subject to the option vest on December 8, 2017, and 1/36th of the shares subject to the option vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.